Mondayitis Could Have a Deadly Effect On Your Body
Modern society has built up Mondays to be the least-liked day of the week. We've just come back from a relaxing weekend and now have to face all the responsibilities we've been ignoring, knowing there's the longest possible time before another weekend.
Not only did a recent study by researchers from the University of Hong Kong (HKU) identify a link between anxiety towards the first day of the working week and elevated levels of a stress hormone, the connection persisted even after retirement.
While correlations do not equal causation, a jump in the stress signal cortisol is closely connected with risk of illnesses. Which could explain why a 2005 meta-analysis found that there's anywhere up to a 19 percent increase in cardiovascular events on Mondays compared to other days of the week.
Related:
In this latest study, researchers investigated a possible link between feelings of anxiety towards Mondays and physical health.
The team examined 3,511 adults aged 50 years and over, taking part in the English Longitudinal Study of Aging (ELSA). Participants reported their levels of anxiety on different days of the week, while hair samples were also taken and analyzed for levels of the stress hormone cortisol.
The study found that people who reported feeling particularly anxious on Mondays had cortisol levels around 23 percent higher than those who felt anxious on other days.
This association seems to suggest that Monday anxiety affects the hypothalamic-pituitary-adrenal (HPA) axis, the body's main stress management system. But chronic stress can overstimulate the HPA axis and lead to immune system issues, metabolic diseases like cancer or diabetes, and cardiovascular disease.
This could be the biological mechanism behind the earlier findings of increases in cardiovascular events on Mondays, suggests the team on the new study.
It might seem like an obvious work-related hazard, but strangely the study found that even retirees still felt higher stress levels on Mondays, along with the negative health effects.
"Mondays act as a cultural 'stress amplifier'," says Tarani Chandola, sociologist at HKU. "For some older adults, the week's transition triggers a biological cascade that lingers for months. This isn't about work – it's about how deeply ingrained Mondays are in our stress physiology, even after careers end."
Maybe Garfield was onto something.
The research was published in the Journal of Affective Disorders.
Cannabis Use Is Linked to Epigenetic Changes, Scientists Discover
To Tackle Our Obesity Crisis, Experts Say Everything We Do Must Change
Big City Lights Could Be Damaging Your Heart Health
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Blood Flow Measurement Devices Market to Surpass USD 1,652.1 Million by 2032, Driven by Rising Demand for Non-Invasive Diagnostics
Burlingame, CA, July 14, 2025 (GLOBE NEWSWIRE) -- The global Blood Flow Measurement Devices Market is estimated to be valued at USD 886.0 Mn in 2025 and is expected to reach USD 1,652.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2025 to 2032. The demand for blood flow measurement devices is projected to rise steadily, driven by several key factors. These include a growing elderly population, an increasing prevalence of cardiovascular diseases, and a rising preference for minimally invasive surgical procedures. Technological advancements particularly in Doppler ultrasound systems are enhancing the accuracy and efficiency of blood flow detection and analysis, further propelling market expansion. However, the high cost of these advanced devices may pose a challenge and potentially limit broader adoption. Request Sample Report: Global Blood Flow Measurement Devices Market Key Takeaways According to Coherent Market Insights (CMI), the global blood flow measurement devices market size is expected to grow significantly during the forecast period, reaching USD 886 Mn in 2025 and USD 1,652.1 Mn by 2032. Global demand for blood flow measurement devices is projected to increase at a CAGR of 9.3% between 2025 and 2032. Laser Doppler blood flowmeters are expected to remain the top-selling product type, generating market revenue of about USD 314.5 Mn in 2025. Based on application, cardiovascular disease segment is expected to account for 45.5% of the global blood flow measurement devices market share in 2025. North America is set to remain the undisputed leader in the blood flow measurement devices industry, accounting for more than two-fifths of the global market share in 2025 Asia Pacific is expected to emerge as a hotbed for blood flood measurement device manufacturers during the assessment period. This is due to rising incidence of cardiovascular diseases and favorable government support. Rising Chronic Disease Burden Spurring Market Growth Coherent Market Insights' latest blood flow measurement devices market analysis offers insights into major factors driving industry growth. One such prominent growth driver is the increasing incidence of chronic diseases. Growing prevalence of cardiovascular and peripheral vascular diseases like atherosclerosis and hypertension is significantly driving demand for blood flow measurement devices. These devices enable real-time monitoring of blood circulation, which is essential for early detection, diagnosis, and timely medical intervention. Immediate Delivery Available | Buy This Premium Research Report: High Cost of Advanced Devices Limiting Market Growth The future blood flow measurement devices market outlook appears optimistic. However, high cost of advanced blood flow measurement devices is a significant barrier to widespread market expansion. Cutting-edge blood flow measurement systems like Doppler and electromagnetic flowmeters are quite expensive. This high cost deters small and medium-sized hospitals and clinics from adopting these technologies, leading to reduced overall blood flow measurement devices market demand. Rising Preference for Non-Invasive Diagnostic Tools Creating Growth Opportunities There is a growing preference for non-invasive and painless methods for measuring blood flow in the modern world. This is expected to uplift demand for advanced blood flow measurement devices, opening lucrative growth prospects for industry players. Increasing geriatric population is also creating growth opportunities for manufacturers of blood flow measurement devices. This is because elderly people are more susceptible to vascular disorders and diabetes, which require blood flow assessments. Impact of AI on the Blood Flow Measurement Devices Market Artificial Intelligence (AI) is becoming a powerful tool in the blood flow measurement devices market. It significantly enhances diagnostic precision, enables real-time monitoring, and expands these tools into wearable and telehealth applications. Advanced analytics powered by AI and machine learning help detect subtle changes in blood flow that human observers might miss. This results in improved accuracy and predictiveness. IoT and cloud integration enable remote monitoring and timely clinician alerts for vascular issues. Key players are developing smart ultrasound and PPG systems with edge AI for cuffless, low-power measurements in wearables and point-of-care devices. Emerging Blood Flow Measurement Devices Market Trends Technological advancements in blood flow measurement systems are breathing new life into the market. Companies are constantly developing advanced Doppler ultrasound and electromagnetic blood flowmeters to improve accuracy, sensitivity, and efficiency of diagnostic procedures. Portable and wearable blood flow measurement devices are gaining immense traction in clinical and homecare settings. Rising adoption of these compact and user-friendly solutions is expected to foster growth of the blood flow measurement devices market in the coming years. Increasing number of surgical and diagnostic procedures is also contributing to rising sales of blood flow measurement devices. These devices are being widely used for blood flow monitoring during vascular surgeries, organ transplants, and reconstructive procedures for better outcomes. Growing number of surgical and diagnostic procedures is contributing to rising sales of blood flow measurement devices. These devices are increasingly used during vascular surgeries, organ transplants, and reconstructive procedures to monitor blood flow and ensure optimal patient outcomes. Request for Customization: Analyst's View said senior analyst Komal Dighe. Current Events and Their Impact on the Blood Flow Measurement Devices Market Event Description and Impact Rising Cardiovascular Complications Linked to Long COVID and Post-COVID Conditions Description: Recent studies highlight a significant increase in vascular complications in post-COVID patients, especially microvascular dysfunction. Impact: This is pushing hospitals and research centers to invest in advanced blood flow measurement tools like laser Doppler and perfusion imaging to track subtle circulatory anomalies in recovering patients. AI Integration in Hemodynamic Monitoring Devices Description: Leading blood flow measurement device companies are launching AI-enabled Doppler and transit-time flow meters that automatically interpret flow data and flag anomalies in real time. Impact: These innovations are reducing clinician burden and enhancing early diagnosis, leading to faster adoption in both high-end hospitals and outpatient care settings. Regulatory Approvals and Reimbursements Description: Recent FDA and CE approvals for innovative blood flow measurement systems (e.g., laser Doppler flowmetry, transit-time flow meters) improve market trust. Impact: Such approvals strengthen commercialization prospects and encourage new product launches by key market players. Competitor InsightsKey companies listed in the blood flow measurement devices market report include: Medistim ASA Cook Medical Inc. Perimed AB Transonic Systems Inc. Atys Medical Getinge Group Deltex Medical Group PLC Biopac Systems Inc. ADInstruments Fluke Biomedical Compumedics Moor Instruments Ltd. ArjoHuntleigh Inc. SONOTEC GmbH NDS Surgical Imaging Cheetah Medical Koven Technology D.E. Hokie & Associates Nihon Kohden Corporation GSI Group Key Developments In July 2024, Getinge introduced Pulsiocare, a cutting-edge hemodynamic monitoring platform built on its award-winning standard user interface. The new advanced device offers a modern and intuitive-to-use platform for hemodynamic assessment and patient monitoring. In October 2024, Researchers at the California Institute created a laser-based, head‑worn device that noninvasively monitors cerebral blood flow and volume using speckle contrast optical spectroscopy (SCOS). This novel device offers a direct method of assessing stroke risk based on physiological markers. Market Segmentation: By Product Type Laser Doppler Blood Flowmeters Ultrasonic Doppler Blood Flowmeters Electromagnetic Blood Flowmeters By Application Cardiovascular Disease Tumor Monitoring Gastroenterology Diabetes Dermatology Others By End User Hospital Clinics Ambulatory Surgical Centers Specialty Centers Others Region: North America Europe Asia Pacific Latin America Middle East Africa Read More Report:Blood Clot Retrieval Devices Market Analysis and Forecast for 2025-2032Blood Glucose Monitoring Market Size, Share & Trend Analysis Report for 2025-2032Blood Pressure Monitoring Devices Market Size, Share, Trends & Opportunities for 2025-2032 Our Trusted Partners:Worldwide Market Reports, Coherent MI, Stratagem Market InsightsGet Recent News: CONTACT: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Contact Us: Mr. Shah Coherent Market Insights 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States US: + 12524771362 UK: +442039578553 AUS: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@ Website: For Latest Update Follow Us: LinkedIn | Facebook | Twitter
Forbes
an hour ago
- Forbes
Rewriting Genetic Fate: Universal Newborn Genomic Screening Arrives
Tiny baby in grey clothes sleeps on woolen blanket In Destiny's Child No Longer: Rewriting Genetic Fate, we envisioned a world where every newborn would be screened for genetic risks. We see a future in which the randomness of genetic inheritance could be met with knowledge, preparation, and, ultimately, intervention. Today, that vision is rapidly becoming reality on both sides of the Atlantic. The United Kingdom's National Health Service (NHS) has announced a landmark plan to offer whole genome sequencing to every newborn. At the same time, Florida's Sunshine Genetics Act has set the stage for a statewide pilot of newborn genomic screening. These developments are a shift in public health. They stand to transform the diagnosis, prevention, and treatment of rare diseases for generations to UK's Ambitious National Rollout The NHS's new initiative will, over the next decade, provide every newborn in England with comprehensive DNA analysis. This effort builds on the success of the Generation Study. This program sequenced the genomes of 100,000 infants to screen for over 200 rare, treatable genetic conditions. The government has committed £650 million to this program, aiming to move beyond the current heel-prick blood test—which screens for just nine conditions—to a system capable of detecting hundreds of single-gene disorders and risk factors for complex diseases. The program is shifting the NHS from reactive care to proactive, personalized healthcare. By identifying disease risks at birth, the NHS hopes to reduce the burden of illness and extending healthy lifespans. The UK's ambitious newborn genome sequencing program is set to make every newborn in England eligible for whole genome sequencing by 2030. This comprehensive framework positions the UK as a global leader in genomic medicine. Furthmore it is setting a precedent for how large-scale, ethically responsible genetic screening can be integrated into national healthcare systems for the benefit of future Sunshine Genetics Act: A U.S. Model Emerges Across the Atlantic, Florida has surged to the forefront of rare disease research with the passage of the Sunshine Genetics Act. Signed into law in July 2025, this legislation launches a five-year pilot program to sequence the genomes of newborns statewide. The Act allocates $3 million to the Sunshine Genetics Pilot Program. It establishes the Florida Institute for Pediatric Rare Diseases at Florida State University, with additional funding from both state and university sources. The program also focuses on ensuring participation remains voluntary and contingent upon parental consent. The Sunshine Genetics Consortium, formed under the Act, unites leading researchers, clinicians, and biotech innovators from across Florida's top institutions. Their mission: to accelerate diagnosis, pioneer new treatments, and end the diagnostic odyssey faced by families affected by one of the more than 7,000 rare diseases impacting 30 million and Future Directions The initiative by the UK and Florida represents a true shift, one that we predicted, in how we approach disease. Early results from multiple studies have shown that genome sequencing can identify actionable conditions and diseases. Furthermore, genome sequencing can identify these conditions far sooner than traditional screening methods. This enables interventions that can alter the course of a child's life. That said, the path to this new approach is not without challenges. As always, there are ethical concerns to address, including consent, privacy, and the potential for genetic discrimination. All these concerns require oversight, thought, and care. Additionally, equitable access to these technologies is another concern, which is important globally and will remain a pressing issue as new technologies emerge. Ongoing research and public dialogue will be essential to ensure that the benefits of genomic medicine are realized for the Science Consider the story of a family whose newborn was diagnosed with a rare metabolic disorder through genomic screening, years before symptoms would have appeared. Early intervention allowed for dietary modifications that prevented irreversible neurological damage. Stories like these are increasingly common as these programs expand. They underscore the human impact of scientific progress. As predicted in Destiny's Child No Longer, the era of universal newborn genomic screening is dawning. The UK and Florida are leading the way. They demonstrate both the promise and the responsibility that comes with rewriting genetic fate. Their experiences will inform global efforts. They will shape a future where every child's genetic destiny is not only known but can be changed for the better.
Bloomberg
2 hours ago
- Bloomberg
LEO Pharma Adds Skin Drug from Boehringer as It Readies for IPO
LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the Danish dermatology specialist strengthens its portfolio ahead of a planned initial public offering in 2026. Under the deal, LEO Pharma will take over global commercialization and further development of the drug, which treats generalized pustular psoriasis, or GPP, a rare and potentially life-threatening condition, LEO said in press release on Monday. Boehringer will receive an upfront payment of €90 million ($110 million) and is eligible for future milestone and royalty payments.
